Published in J Biol Chem on December 28, 2001
Deregulated proteolysis by the F-box proteins SKP2 and beta-TrCP: tipping the scales of cancer. Nat Rev Cancer (2008) 6.10
Claudin-1 regulates cellular transformation and metastatic behavior in colon cancer. J Clin Invest (2005) 3.02
Nf-kappa B, chemokine gene transcription and tumour growth. Nat Rev Immunol (2002) 2.81
The ubiquitin-editing enzyme A20 requires RNF11 to downregulate NF-kappaB signalling. EMBO J (2009) 2.17
NLRP12 suppresses colon inflammation and tumorigenesis through the negative regulation of noncanonical NF-κB signaling. Immunity (2012) 2.07
NF-kappaB activation in melanoma. Pigment Cell Res (2006) 1.55
Chemosensitivity of conjunctival melanoma cell lines to target-specific chemotherapeutic agents. Graefes Arch Clin Exp Ophthalmol (2012) 1.42
Role of nuclear factor-kappa B in melanoma. Cancer Metastasis Rev (2005) 1.41
Genetic and epigenetic loss of microRNA-31 leads to feed-forward expression of EZH2 in melanoma. Oncotarget (2012) 1.36
NF-kappaB regulates androgen receptor expression and prostate cancer growth. Am J Pathol (2009) 1.35
High basal NF-κB activity in nonpigmented melanoma cells is associated with an enhanced sensitivity to vitamin D3 derivatives. Br J Cancer (2011) 1.35
HIF-1alpha regulates epithelial inflammation by cell autonomous NFkappaB activation and paracrine stromal remodeling. Blood (2008) 1.33
Targeting mutant (V600E) B-Raf in melanoma interrupts immunoediting of leukocyte functions and melanoma extravasation. Cancer Res (2007) 1.31
NF-κB inducing kinase: a key regulator in the immune system and in cancer. Cytokine Growth Factor Rev (2010) 1.28
Cancer biomarker discovery: the entropic hallmark. PLoS One (2010) 1.26
FAP-1 association with Fas (Apo-1) inhibits Fas expression on the cell surface. Mol Cell Biol (2003) 1.20
P2 receptors and neuronal injury. Pflugers Arch (2006) 1.18
RAS/RAF/MEK/ERK and PI3K/PTEN/AKT Signaling in Malignant Melanoma Progression and Therapy. Dermatol Res Pract (2011) 1.15
NF-κB as potential target in the treatment of melanoma. J Transl Med (2012) 1.14
The Role of B-RAF Mutations in Melanoma and the Induction of EMT via Dysregulation of the NF-κB/Snail/RKIP/PTEN Circuit. Genes Cancer (2010) 1.14
The Fbw7 and betaTRCP E3 ubiquitin ligases and their roles in tumorigenesis. Front Biosci (Landmark Ed) (2012) 1.12
Understanding signaling cascades in melanoma. Photochem Photobiol (2007) 1.10
Inflammatory cytokines promote mesenchymal transformation in embryonic and adult valve endothelial cells. Arterioscler Thromb Vasc Biol (2012) 1.09
Inhibition of c-Jun NH2-terminal kinase or extracellular signal-regulated kinase improves lung injury. Respir Res (2004) 1.08
Differential regulation of CXC ligand 1 transcription in melanoma cell lines by poly(ADP-ribose) polymerase-1. Oncogene (2006) 1.06
Arsenite sensitizes human melanomas to apoptosis via tumor necrosis factor alpha-mediated pathway. J Biol Chem (2004) 1.06
Brain-derived neurotrophic factor induces proliferation of human airway smooth muscle cells. J Cell Mol Med (2012) 1.05
Protein kinase C inhibitor AEB071 targets ocular melanoma harboring GNAQ mutations via effects on the PKC/Erk1/2 and PKC/NF-κB pathways. Mol Cancer Ther (2012) 1.03
Tris (dibenzylideneacetone) dipalladium, a N-myristoyltransferase-1 inhibitor, is effective against melanoma growth in vitro and in vivo. Clin Cancer Res (2008) 1.03
NF-κB and STAT1 control CXCL1 and CXCL2 gene transcription. Am J Physiol Endocrinol Metab (2013) 1.02
Axonal neuregulin 1 type III activates NF-kappaB in Schwann cells during myelin formation. J Biol Chem (2010) 0.98
A phase I trial of bortezomib with temozolomide in patients with advanced melanoma: toxicities, antitumor effects, and modulation of therapeutic targets. Clin Cancer Res (2009) 0.98
NF-κB inducing kinase (NIK) modulates melanoma tumorigenesis by regulating expression of pro-survival factors through the β-catenin pathway. Oncogene (2011) 0.97
Cdc25A regulates matrix metalloprotease 1 through Foxo1 and mediates metastasis of breast cancer cells. Mol Cell Biol (2011) 0.96
Fine tuning the transcriptional regulation of the CXCL1 chemokine. Prog Nucleic Acid Res Mol Biol (2003) 0.96
Non-Inflammasome Forming NLRs in Inflammation and Tumorigenesis. Front Immunol (2014) 0.96
Shikonin reduces oedema induced by phorbol ester by interfering with IkappaBalpha degradation thus inhibiting translocation of NF-kappaB to the nucleus. Br J Pharmacol (2010) 0.94
Prolonged exposure to acid and bile induces chromosome abnormalities that precede malignant transformation of benign Barrett's epithelium. Mol Cytogenet (2012) 0.93
Nitrosylcobalamin potentiates the anti-neoplastic effects of chemotherapeutic agents via suppression of survival signaling. PLoS One (2007) 0.92
Macrophage inhibitory cytokine-1 regulates melanoma vascular development. Am J Pathol (2010) 0.91
The lymphotoxin-beta receptor is an upstream activator of NF-kappaB-mediated transcription in melanoma cells. J Biol Chem (2008) 0.91
Augmentation of therapeutic responses in melanoma by inhibition of IRAK-1,-4. Cancer Res (2012) 0.90
Fisetin inhibits human melanoma cell invasion through promotion of mesenchymal to epithelial transition and by targeting MAPK and NFκB signaling pathways. PLoS One (2014) 0.90
Signaling from p53 to NF-kappa B determines the chemotherapy responsiveness of neuroblastoma. Neoplasia (2006) 0.90
NF-kappaB mediates mitogen-activated protein kinase pathway-dependent iNOS expression in human melanoma. J Invest Dermatol (2008) 0.89
Retracted Oleandrin-mediated expression of Fas potentiates apoptosis in tumor cells. J Clin Immunol (2006) 0.88
Tea catechins as inhibitors of receptor tyrosine kinases: mechanistic insights and human relevance. Pharmacol Res (2010) 0.87
Effective inhibition of melanoma by BI-69A11 is mediated by dual targeting of the AKT and NF-κB pathways. Pigment Cell Melanoma Res (2011) 0.87
Emerging significance of NLRs in inflammatory bowel disease. Inflamm Bowel Dis (2014) 0.86
n-3 Fatty acids block TNF-α-stimulated MCP-1 expression in rat mesangial cells. Am J Physiol Renal Physiol (2011) 0.86
The TRAF3 adaptor protein drives proliferation of anaplastic large cell lymphoma cells by regulating multiple signaling pathways. Cell Cycle (2014) 0.85
Elevated CXCL1 expression in breast cancer stroma predicts poor prognosis and is inversely associated with expression of TGF-β signaling proteins. BMC Cancer (2014) 0.84
Role of Nlrp6 and Nlrp12 in the maintenance of intestinal homeostasis. Eur J Immunol (2014) 0.84
Chemokines, chemokine receptors and the gastrointestinal system. World J Gastroenterol (2013) 0.82
Alpha-catulin contributes to drug-resistance of melanoma by activating NF-κB and AP-1. PLoS One (2015) 0.81
A novel tumor suppressor miRNA miR-520e contributes to suppression of hepatoma. Acta Pharmacol Sin (2012) 0.81
Protein ubiquitination in lymphoid malignancies. Immunol Rev (2015) 0.80
Computational approaches for discovery of common immunomodulators in fungal infections: towards broad-spectrum immunotherapeutic interventions. BMC Microbiol (2013) 0.79
The serine protease plasmin triggers expression of the CC-chemokine ligand 20 in dendritic cells via Akt/NF-κB-dependent pathways. J Biomed Biotechnol (2012) 0.79
Tetrahydroanthraquinone Derivative (±)-4-Deoxyaustrocortilutein Induces Cell Cycle Arrest and Apoptosis in Melanoma Cells via Upregulation of p21 and p53 and Downregulation of NF-kappaB. J Cancer (2016) 0.78
Down-regulation of S100A9 inhibits osteosarcoma cell growth through inactivating MAPK and NF-κB signaling pathways. BMC Cancer (2016) 0.78
PLX4032 Mediated Melanoma Associated Antigen Potentiation in Patient Derived Primary Melanoma Cells. J Cancer (2015) 0.77
MCPIP1 Regulates Fibroblast Migration in 3-D Collagen Matrices Downstream of MAP Kinases and NF-κB. J Invest Dermatol (2015) 0.77
Drug targets and predictive biomarkers in the management of metastatic melanoma. Pharmgenomics Pers Med (2012) 0.77
Nuclear factor-κB expression is predictive of overall survival in patients with cutaneous melanoma. Oncol Lett (2010) 0.77
Expression of the class 1 histone deacetylases HDAC8 and 3 are associated with improved survival of patients with metastatic melanoma. Mod Pathol (2015) 0.77
Direct anti-inflammatory effects of angiotensin-(1-7) on microglia. J Neurochem (2015) 0.76
NF-kB2 induces senescence bypass in melanoma via a direct transcriptional activation of EZH2. Oncogene (2015) 0.76
An assessment of gene-by-gene interactions as a tool to unfold missing heritability in dyslexia. Hum Genet (2015) 0.76
Pathogenic Lifestyles of E. coli Pathotypes in a Standardized Epithelial Cell Model Influence Inflammatory Signaling Pathways and Cytokines Secretion. Front Cell Infect Microbiol (2016) 0.75
NF-kappaΒ-inducing kinase regulates stem cell phenotype in breast cancer. Sci Rep (2016) 0.75
The C11R gene, which encodes the vaccinia virus growth factor, is partially responsible for MVA-induced NF-κB and ERK2 activation. J Virol (2012) 0.75
Peimine Inhibits the Production of Proinflammatory Cytokines Through Regulation of the Phosphorylation of NF-κB and MAPKs in HMC-1 Cells. Pharmacogn Mag (2017) 0.75
Quinacrine for extremity melanoma in a mouse model of isolated limb perfusion (ILP). Surg Today (2014) 0.75
The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol (1996) 22.30
An essential role for NF-kappaB in preventing TNF-alpha-induced cell death. Science (1996) 13.87
A cytokine-responsive IkappaB kinase that activates the transcription factor NF-kappaB. Nature (1997) 11.31
The IkappaB kinase complex (IKK) contains two kinase subunits, IKKalpha and IKKbeta, necessary for IkappaB phosphorylation and NF-kappaB activation. Cell (1997) 8.74
IkappaB kinase-beta: NF-kappaB activation and complex formation with IkappaB kinase-alpha and NIK. Science (1997) 7.57
Identification and characterization of an IkappaB kinase. Cell (1997) 6.71
MAP3K-related kinase involved in NF-kappaB induction by TNF, CD95 and IL-1. Nature (1997) 6.53
Positive and negative regulation of IkappaB kinase activity through IKKbeta subunit phosphorylation. Science (1999) 5.95
How NF-kappaB is activated: the role of the IkappaB kinase (IKK) complex. Oncogene (1999) 4.33
NF-kappaB activation by a signaling complex containing TRAF2, TANK and TBK1, a novel IKK-related kinase. EMBO J (1999) 3.78
Constitutive overexpression of a growth-regulated gene in transformed Chinese hamster and human cells. Proc Natl Acad Sci U S A (1987) 3.74
Tumor necrosis factor receptor-associated factors (TRAFs)--a family of adapter proteins that regulates life and death. Genes Dev (1998) 3.33
Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene (1999) 3.32
Molecular characterization and chromosomal mapping of melanoma growth stimulatory activity, a growth factor structurally related to beta-thromboglobulin. EMBO J (1988) 3.26
Defective lymphotoxin-beta receptor-induced NF-kappaB transcriptional activity in NIK-deficient mice. Science (2001) 3.11
NF-kappaB-inducing kinase activates IKK-alpha by phosphorylation of Ser-176. Proc Natl Acad Sci U S A (1998) 3.04
Differential regulation of IkappaB kinase alpha and beta by two upstream kinases, NF-kappaB-inducing kinase and mitogen-activated protein kinase/ERK kinase kinase-1. Proc Natl Acad Sci U S A (1998) 2.76
NF-kappaB activation: the I kappaB kinase revealed? Cell (1997) 2.73
The IKK complex: an integrator of all signals that activate NF-kappaB? Trends Cell Biol (2000) 2.68
c-Jun N-terminal phosphorylation correlates with activation of the JNK subgroup but not the ERK subgroup of mitogen-activated protein kinases. Mol Cell Biol (1994) 2.41
Induction of interleukin-8 synthesis integrates effects on transcription and mRNA degradation from at least three different cytokine- or stress-activated signal transduction pathways. Mol Cell Biol (1999) 2.39
Autocrine and paracrine regulation by cytokines and growth factors in melanoma. Cytokine (2000) 2.25
A constitutively active and nuclear form of the MAP kinase ERK2 is sufficient for neurite outgrowth and cell transformation. Curr Biol (1998) 2.20
The p38 mitogen-activated protein kinase is required for NF-kappaB-dependent gene expression. The role of TATA-binding protein (TBP). J Biol Chem (1999) 2.11
The Rel/NF-kappa B family: friend and foe. Trends Biochem Sci (2000) 1.90
Constitutive IkappaB kinase activity correlates with nuclear factor-kappaB activation in human melanoma cells. Cancer Res (2001) 1.79
HMGI(Y) and Sp1 in addition to NF-kappa B regulate transcription of the MGSA/GRO alpha gene. Nucleic Acids Res (1995) 1.74
Coordinate regulation of IkappaB kinases by mitogen-activated protein kinase kinase kinase 1 and NF-kappaB-inducing kinase. Mol Cell Biol (1998) 1.65
Cloning of rat MEK kinase 1 cDNA reveals an endogenous membrane-associated 195-kDa protein with a large regulatory domain. Proc Natl Acad Sci U S A (1996) 1.57
Enhanced degradation of I-kappaB alpha contributes to endogenous activation of NF-kappaB in Hs294T melanoma cells. Cancer Res (1997) 1.27
Constitutive and cytokine-induced expression of the melanoma growth stimulatory activity/GRO alpha gene requires both NF-kappa B and novel constitutive factors. J Biol Chem (1995) 1.26
A constitutive active MEK --> ERK pathway negatively regulates NF-kappa B-dependent gene expression by modulating TATA-binding protein phosphorylation. J Biol Chem (2000) 1.17
Signal-induced degradation of I(kappa)B(alpha): association with NF-kappaB and the PEST sequence in I(kappa)B(alpha) are not required. Mol Cell Biol (1996) 1.17
Nuclear factor-kappa B activation by the CXC chemokine melanoma growth-stimulatory activity/growth-regulated protein involves the MEKK1/p38 mitogen-activated protein kinase pathway. J Biol Chem (2000) 1.14
Anergic T cells are defective in both jun NH2-terminal kinase and mitogen-activated protein kinase signaling pathways. J Exp Med (1996) 1.13
MGSA/GRO transcription is differentially regulated in normal retinal pigment epithelial and melanoma cells. Mol Cell Biol (1994) 1.12
The NF-kappa B-inducing kinase induces PC12 cell differentiation and prevents apoptosis. J Biol Chem (2000) 1.12
Elevated constitutive IkappaB kinase activity and IkappaB-alpha phosphorylation in Hs294T melanoma cells lead to increased basal MGSA/GRO-alpha transcription. Cancer Res (1999) 1.11
Involvement of extracellular signal-regulated kinase module in HIV-mediated CD4 signals controlling activation of nuclear factor-kappa B and AP-1 transcription factors. J Immunol (1998) 1.09
Role of IKKgamma/nemo in assembly of the Ikappa B kinase complex. J Biol Chem (2000) 1.08
Recombinant expression, biochemical characterization, and biological activities of the human MGSA/gro protein. Biochemistry (1990) 1.02
Differential effects of lipopolysaccharide and tumor necrosis factor on monocytic IkappaB kinase signalsome activation and IkappaB proteolysis. J Biol Chem (1999) 1.01
The p38 MAP kinase inhibitor SB203580 enhances nuclear factor-kappa B transcriptional activity by a non-specific effect upon the ERK pathway. Br J Pharmacol (2000) 0.99
Both amino- and carboxyl-terminal domains of TRAF3 negatively regulate NF-kappaB activation induced by OX40 signaling. Biochem Biophys Res Commun (2000) 0.94
Tumor necrosis factor-alpha induces distinctive NF-kappa B signaling within human dermal fibroblasts. J Biol Chem (2000) 0.81
Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell (2008) 6.78
Role of chemokines in tumor growth. Cancer Lett (2007) 3.36
Chemokines and chemokine receptors: new insights into cancer-related inflammation. Trends Mol Med (2010) 3.10
Mouse xenograft models vs GEM models for human cancer therapeutics. Dis Model Mech (2008) 2.37
CXCL1 induced by prostaglandin E2 promotes angiogenesis in colorectal cancer. J Exp Med (2006) 2.30
Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials. PLoS One (2012) 2.21
Constitutive activation of Akt/protein kinase B in melanoma leads to up-regulation of nuclear factor-kappaB and tumor progression. Cancer Res (2002) 2.19
Role of CXCL1 in tumorigenesis of melanoma. J Leukoc Biol (2002) 2.13
Effects of flow and diffusion on chemotaxis studies in a microfabricated gradient generator. Lab Chip (2005) 2.11
The Duffy antigen receptor for chemokines transports chemokines and supports their promigratory activity. Nat Immunol (2008) 2.08
Involvement of CC chemokine ligand 18 (CCL18) in normal and pathological processes. J Leukoc Biol (2005) 1.80
Rab11-family interacting protein 2 and myosin Vb are required for CXCR2 recycling and receptor-mediated chemotaxis. Mol Biol Cell (2004) 1.70
Chemokines in health and disease. Exp Cell Res (2011) 1.69
Chemokine receptor internalization and intracellular trafficking. Cytokine Growth Factor Rev (2005) 1.59
NF-kappaB activation in melanoma. Pigment Cell Res (2006) 1.55
BMS-345541 targets inhibitor of kappaB kinase and induces apoptosis in melanoma: involvement of nuclear factor kappaB and mitochondria pathways. Clin Cancer Res (2006) 1.54
Augmenting chemosensitivity of malignant melanoma tumors via proteasome inhibition: implication for bortezomib (VELCADE, PS-341) as a therapeutic agent for malignant melanoma. Cancer Res (2004) 1.51
The Duffy antigen modifies systemic and local tissue chemokine responses following lipopolysaccharide stimulation. J Immunol (2006) 1.50
Cytokine receptor CXCR4 mediates estrogen-independent tumorigenesis, metastasis, and resistance to endocrine therapy in human breast cancer. Cancer Res (2010) 1.45
Role of nuclear factor-kappa B in melanoma. Cancer Metastasis Rev (2005) 1.41
Differential regulation of CXCR2 trafficking by Rab GTPases. Blood (2002) 1.38
Monomeric and dimeric CXCL8 are both essential for in vivo neutrophil recruitment. PLoS One (2010) 1.29
Conditional ablation of Ikkb inhibits melanoma tumor development in mice. J Clin Invest (2010) 1.28
NF-κB inducing kinase: a key regulator in the immune system and in cancer. Cytokine Growth Factor Rev (2010) 1.28
Parallel phosphatidylinositol 3-kinase (PI3K)-dependent and Src-dependent pathways lead to CXCL8-mediated Rac2 activation and chemotaxis. J Biol Chem (2008) 1.25
Altered CXCR2 signaling in beta-arrestin-2-deficient mouse models. J Immunol (2005) 1.25
CXC chemokines and their receptors: a case for a significant biological role in cutaneous wound healing. Histol Histopathol (2008) 1.23
Systemic targeting inhibitor of kappaB kinase inhibits melanoma tumor growth. Cancer Res (2007) 1.19
The role of chemokines in intestinal inflammation and cancer. Curr Opin Pharmacol (2009) 1.16
VASP is a CXCR2-interacting protein that regulates CXCR2-mediated polarization and chemotaxis. J Cell Sci (2009) 1.13
Hypoxia enhances CXCR4 expression in human microvascular endothelial cells and human melanoma cells. Eur Cytokine Netw (2007) 1.13
Deletion of the COOH-terminal domain of CXC chemokine receptor 4 leads to the down-regulation of cell-to-cell contact, enhanced motility and proliferation in breast carcinoma cells. Cancer Res (2006) 1.12
Targeting aurora kinases limits tumour growth through DNA damage-mediated senescence and blockade of NF-κB impairs this drug-induced senescence. EMBO Mol Med (2012) 1.10
RAF265 inhibits the growth of advanced human melanoma tumors. Clin Cancer Res (2012) 1.09
The angiostatic activity of interferon-inducible protein-10/CXCL10 in human melanoma depends on binding to CXCR3 but not to glycosaminoglycan. Mol Ther (2004) 1.06
The IL sequence in the LLKIL motif in CXCR2 is required for full ligand-induced activation of Erk, Akt, and chemotaxis in HL60 cells. J Biol Chem (2006) 1.05
Hsc/Hsp70 interacting protein (hip) associates with CXCR2 and regulates the receptor signaling and trafficking. J Biol Chem (2001) 1.02
Potential role for Duffy antigen chemokine-binding protein in angiogenesis and maintenance of homeostasis in response to stress. J Leukoc Biol (2002) 1.00
The carboxyl-terminal PDZ ligand motif of chemokine receptor CXCR2 modulates post-endocytic sorting and cellular chemotaxis. J Biol Chem (2008) 1.00
PAK1 kinase is required for CXCL1-induced chemotaxis. Biochemistry (2002) 0.99
Opposing roles of murine duffy antigen receptor for chemokine and murine CXC chemokine receptor-2 receptors in murine melanoma tumor growth. Cancer Res (2007) 0.98
A phase I trial of bortezomib with temozolomide in patients with advanced melanoma: toxicities, antitumor effects, and modulation of therapeutic targets. Clin Cancer Res (2009) 0.98
Antioxidants tiron and N-acetyl-L-cysteine differentially mediate apoptosis in melanoma cells via a reactive oxygen species-independent NF-kappaB pathway. Free Radic Biol Med (2007) 0.97
Impaired healing of nitrogen mustard wounds in CXCR2 null mice. Wound Repair Regen (2003) 0.97
RhoB plays an essential role in CXCR2 sorting decisions. J Cell Sci (2007) 0.96
Fine tuning the transcriptional regulation of the CXCL1 chemokine. Prog Nucleic Acid Res Mol Biol (2003) 0.96
LIM and SH3 protein-1 modulates CXCR2-mediated cell migration. PLoS One (2010) 0.94
Microfluidic switching system for analyzing chemotaxis responses of wortmannin-inhibited HL-60 cells. Biomed Microdevices (2008) 0.92
The chemokine receptors CXCR1 and CXCR2 couple to distinct G protein-coupled receptor kinases to mediate and regulate leukocyte functions. J Immunol (2012) 0.92
The lymphotoxin-beta receptor is an upstream activator of NF-kappaB-mediated transcription in melanoma cells. J Biol Chem (2008) 0.91
CXCR4 drives the metastatic phenotype in breast cancer through induction of CXCR2 and activation of MEK and PI3K pathways. Mol Biol Cell (2014) 0.90
The dynamic yin-yang interaction of CXCR4 and CXCR7 in breast cancer metastasis. Breast Cancer Res (2012) 0.88
Expression of activated Akt in benign nevi, Spitz nevi and melanomas. J Cutan Pathol (2007) 0.87
IQGAP1 is a novel CXCR2-interacting protein and essential component of the "chemosynapse". PLoS One (2011) 0.87
The C-terminal domain LLKIL motif of CXCR2 is required for ligand-mediated polarization of early signals during chemotaxis. J Cell Sci (2004) 0.86
Functional characterization of chimpanzee cytomegalovirus chemokine, vCXCL-1(CCMV). Virology (2007) 0.86
INK4a/ARF [corrected] inactivation with activation of the NF-κB/IL-6 pathway is sufficient to drive the development and growth of angiosarcoma. Cancer Res (2012) 0.85
Molecular determinants of melanoma malignancy: selecting targets for improved efficacy of chemotherapy. Mol Cancer Ther (2009) 0.85
Passage-dependent cancerous transformation of human mesenchymal stem cells under carcinogenic hypoxia. FASEB J (2013) 0.84
Preparation of (-)-Nutlin-3 using enantioselective organocatalysis at decagram scale. J Org Chem (2013) 0.84
Phase II trial of bortezomib plus doxorubicin in hepatocellular carcinoma (E6202): a trial of the Eastern Cooperative Oncology Group. Invest New Drugs (2014) 0.83
CCAAT displacement protein regulates nuclear factor-kappa beta-mediated chemokine transcription in melanoma cells. Melanoma Res (2007) 0.83
Cell surface heparan sulfate participates in CXCL1-induced signaling. Biochemistry (2003) 0.83
Bimodal analysis reveals a general scaling law governing nondirected and chemotactic cell motility. Biophys J (2010) 0.81
Chemokine research moves on. Exp Cell Res (2011) 0.79
Short tail with skin lesion phenotype occurs in transgenic mice with keratin-14 promoter-directed expression of mutant CXCR2. J Leukoc Biol (2008) 0.79
Acute Inhibition of MEK Suppresses Congenital Melanocytic Nevus Syndrome in a Murine Model Driven by Activated NRAS and Wnt Signaling. J Invest Dermatol (2015) 0.78
Chemokines, macrophage inflammatory protein-2 and stromal cell-derived factor-1α, suppress amyloid β-induced neurotoxicity. Toxicol Appl Pharmacol (2011) 0.78
Adaptor protein2 (AP2) orchestrates CXCR2-mediated cell migration. Traffic (2014) 0.78
Micrometastatic Dormancy in Uveal Melanoma: A Comprehensive Review of the Evidence, Mechanisms, and Implications for Future Adjuvant Therapies. Int Ophthalmol Clin (2017) 0.75
The Meharry-Vanderbilt-Tennessee State University Cancer Partnership (MVTCP): History and Highlights of 20 Years of Accomplishments. J Health Care Poor Underserved (2022) 0.75